Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system

Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system

Abstract Background Monitoring of anticoagulant activity of direct oral anticoagulants (DOACs) can be necessary in special situations. DOAC plasma levels have a high inter‐ and intraindividual variation and do not necessarily reflect the coagulation status of the patient. Thrombin generation (TG) is...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Christian Pfrepper, Michael Metze, Annelie Siegemund, Tristan Klöter, Thomas Siegemund, Sirak Petros
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Elsevier 2020-05-01
Reeks:	Research and Practice in Thrombosis and Haemostasis
Onderwerpen:	anti‐Xa‐inhibitors correlation dabigatran DOAC plasma levels ST Genesia thrombin generation
Online toegang:	https://doi.org/10.1002/rth2.12340

Gelijkaardige items

Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
door: Michael Metze, et al.
Gepubliceerd in: (2020-05-01)

Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between‐subject variation
door: Søren Risom Kristensen, et al.
Gepubliceerd in: (2022-01-01)

Calibrated automated thrombogram II: removing barriers for thrombin generation measurements
door: P. L. A. Giesen, et al.
Gepubliceerd in: (2021-08-01)

Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants
door: Styliani Papadaki, et al.
Gepubliceerd in: (2021-08-01)

The novel anticoagulants: entering a new era
door: Swiss Medical Weekly
Gepubliceerd in: (2009-02-01)

Semi-automated thrombin dynamics applying the ST Genesia thrombin generation assay
door: Audrey Carlo, et al.
Gepubliceerd in: (2022-07-01)

Direct oral anticoagulant blood level monitoring in daily practice
door: R. Bavalia, et al.
Gepubliceerd in: (2021-05-01)

Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram
door: Tuukka A. Helin, et al.
Gepubliceerd in: (2021-03-01)

Thrombocytopenia induced by dabigatran: two case reports
door: Hyun Goo Kang, et al.
Gepubliceerd in: (2017-06-01)

Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort
door: Tom W. van de Berg, et al.
Gepubliceerd in: (2022-10-01)

Thrombin-induced platelet aggregation −effect of dabigatran using automated platelet aggregometry−
door: Mie Shimizu, et al.
Gepubliceerd in: (2020-04-01)

Practical issues in measuring the anticoagulant effect of direct oral anticoagulants
door: Dopsaj Violeta
Gepubliceerd in: (2020-01-01)

Dabigatran Plasma Measurement to Guide the Management of Acute Bleeding and Thrombotic Complications
door: Maurizio Tala, et al.
Gepubliceerd in: (2018-09-01)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
door: Jong-Min Kim, et al.
Gepubliceerd in: (2022-01-01)

Direct oral anticoagulants in cirrhosis: Rationale and current evidenceKeypoints
door: Cindy Pereira Portela, et al.
Gepubliceerd in: (2024-08-01)

Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study
door: Dionne C.W. Braeken, et al.
Gepubliceerd in: (2023-05-01)

Comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs
door: Alex M. Lynch, et al.
Gepubliceerd in: (2024-11-01)

Direct oral anticoagulants; a review for the non-specialist
door: Thilina Gunawardena
Gepubliceerd in: (2021-11-01)

Direct oral anticoagulant: Review article
door: Abdulrahman Nasiri, et al.
Gepubliceerd in: (2022-01-01)

The new way of Dabigatran reversal – Idarucizumab
door: Erwin Ciechański, et al.
Gepubliceerd in: (2019-02-01)

The new way of Dabigatran reversal – Idarucizumab
door: Erwin Ciechański, et al.
Gepubliceerd in: (2019-02-01)

Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022
door: A. V. Matveev, et al.
Gepubliceerd in: (2024-01-01)

Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits
door: Yin Lu, et al.
Gepubliceerd in: (2022-01-01)

Thrombin generation measurement using the ST Genesia Thrombin Generation System in a cohort of healthy adults: Normal values and variability
door: Sara Calzavarini, et al.
Gepubliceerd in: (2019-10-01)

Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review
door: Natalia Atzemian, et al.
Gepubliceerd in: (2023-09-01)

Dabigatran etexilate - A novel oral anticoagulant for bleeding complications
door: Himabindu Reddy, et al.
Gepubliceerd in: (2015-09-01)

Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
door: Shaw Shaw, et al.
Gepubliceerd in: (2023-07-01)

Is There an Alternative Oral Anticoagulation to Vitamin-K-Antagonists for Patients with Mechanical Aortic Valve Replacement? – A Literature Review
door: Stephen Gerfer, et al.
Gepubliceerd in: (2024-05-01)

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
door: Emmanuel J. Favaloro, et al.
Gepubliceerd in: (2022-02-01)

Thrombin and factor Xa link the coagulation system with liver fibrosis
door: Ameet Dhar, et al.
Gepubliceerd in: (2018-05-01)

An update on applications and limitations of direct oral anticoagulants
door: Sharon Wei, et al.
Gepubliceerd in: (2023-04-01)

Analytical performance of the endogenous thrombin potential–based activated protein C resistance assay on the automated ST Genesia system
door: Laure Morimont, et al.
Gepubliceerd in: (2022-03-01)

Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis
door: Marta Smeda, et al.
Gepubliceerd in: (2022-02-01)

Dabigatran mitigates cisplatin-mediated nephrotoxicity through down regulation of thrombin pathway
door: Mohamed Gamal El-Din Ewees, et al.
Gepubliceerd in: (2021-07-01)

Reference values for thrombin dynamics in platelet rich plasma
door: Qiuting Yan, et al.
Gepubliceerd in: (2021-02-01)

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
door: Jana Úlehlová, et al.
Gepubliceerd in: (2021-11-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
door: Maha Al-Ghafry, et al.
Gepubliceerd in: (2022-10-01)

Dabigatran etexilate: a direct thrombin inhibitor
door: M. Dugnani
Gepubliceerd in: (2013-05-01)

Safety of Dabigatran as an Anticoagulant: A Systematic Review and Meta-Analysis
door: Ya Zhou, et al.
Gepubliceerd in: (2021-02-01)

Viscoelastometry for detecting oral anticoagulants
door: Philipp Groene, et al.
Gepubliceerd in: (2021-03-01)